# InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Completes Site Activation and Marks First Patient Completions in Pivotal Phase 3 Alzheimer’s Trial

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that all 84 U.S. sites for its pivotal Phase 3 trial in early Alzheimer’s disease are now fully activated and enrolling, with most already treating patients. The first group of participants has completed the 6-month treatment phase, keeping the company on schedule to deliver symptomatic data in the second half of 2026. CEO Maria Maccecchini said the study, now 25% complete, reflects strong execution and continued momentum toward bringing buntanetap to patients in need of effective therapies.

 To view the full press release, visit https://ibn.fm/xMm33

 About Annovis Bio Inc.

 Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

 NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-annovis-bio-inc-nyse-anvs-completes-site-activation-and-marks-first-patient-completions-in-pivotal-phase-3-alzheimers-trial/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/annovis-bio-activates-all-84-sites-for-alzheimer-s-phase-3-trial/7567024a5da0b2e3afc6a20cce962b4d) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2511/6/camc7LIP.webp)